During the last few years, evidence has accumulated indicating that the protein composition of lipoproteins may be more relevant to atherogenesis and cardiovascular risk than the absolute concentrations of plasma lipids. One of these compositional factors is apolipoprotein (apo) C-III, a small interchangeable apolipoprotein that impairs hepatic uptake of circulating lipoproteins and has various direct proatherogenic effects on the arterial wall. In this study, we prospectively analyzed the association between plasma concentrations of low-density lipoprotein (LDL) that contains or does not contain apoC-III and the appearance of coronary heart disease (CHD) events in Ͼ1400 men and women. Our key finding was that in a multivariate-adjusted model that includes concentrations of both LDL with apoC-III and LDL without apoC-III, only LDL with apoC-III was consistently and significantly associated with risk, indicating that an important fraction of the cardiovascular risk traditionally adjudicated to LDL may in fact be due to LDL with apoC-III. The findings were robust to adjustment for levels of plasma lipids, demographic cardiovascular risk factors, and diabetes status. The identification of LDL with apoC-III as a lipoprotein type disproportionately associated with the development of CHD adds to the enlarging body of evidence suggesting the involvement of apoC-III in atherogenesis and metabolic derangements and should stimulate further research exploring apoC-III as an interventional target in the prevention of CHD. See p 2065.
Insomnia and the Risk of Acute Myocardial Infarction: A Population Study
Insomnia, a subjective feeling of having difficulties initiating or maintaining sleep, or having a feeling of nonrestorative sleep, is a highly prevalent condition in the industrialized world. Only a few prospective studies have investigated insomnia in relation to risk for coronary heart disease, and these prior studies have been subjected to several potential methodological limitations. We assessed insomnia symptoms and risk of acute myocardial infarction in a large population-based study, taking into account the established cardiovascular risk factors, psychological distress, and chronic somatic disorders. In our study, insomnia symptoms were associated with a moderate increase in risk for acute myocardial infarction. The results were fairly robust in different multivariable models and sensitivity analyses. Nevertheless, insomnia is a frequent, easily recognizable, and potentially manageable condition. Treatment options include adherence to simple recommendations concerning sleeping habits, often referred to as sleep hygiene, and several nonpharmacological and pharmacological therapies, with the potential to produce reliable and durable changes among persons who have chronic insomnia. Therefore, evaluation of insomnia might provide additional information in clinical risk assessment that could be useful in cardiovascular prevention. However, further research is needed to better establish the risk associated with insomnia and to reveal the possible pathophysiological mechanisms. See p 2073.
Reduced Degradation of the Chemokine MCP-3 by Matrix Metalloproteinase-2 Exacerbates Myocardial Inflammation in Experimental Viral Cardiomyopathy
Cardiac inflammation is one important pathomechanism in the progression of heart failure. Although in some cardiac diseases inflammation might be helpful (eg, after acute myocardial infarction), uncontrolled inflammation is detrimental in most forms of cardiomyopathy. Insights into the pathophysiological control of inflammation are needed to develop new interventions. Matrix metalloproteinases (MMPs) are deregulated in acute and chronic heart failure. In most studies, the gelatinases MMP-2 and MMP-9 are especially upregulated. Although MMPs were thought to process matrix proteins only and, therefore, trigger remodeling, there is recent evidence that some MMPs process cytokines as well as chemokines, thereby modulating the inflammatory process. This study enhances our knowledge about the immunmodulatory properties of MMPs, especially relative to inflammatory cardiomyopathies. Matrix metalloproteinase 2 degrades the chemokine MCP-3. We show here that this is one beneficial mechanism that controls inflammation during viral myocarditis. Loss of this degradation by MMP-2 knockout increases protein levels of the chemokine MCP-3, which fuels the inflammatory process leading to increased transendothelial migration of inflammatory cells into the cardiac tissue. This experimental overreaction of the immune system could be prevented by neutralizing MCP-3 in vivo. This shows that a complete inhibition of MMP-2 (and similar data exists for MMP-9) is detrimental in experimental viral heart disease. Preservation of MMP-2 should be one goal in treating heart failure with an increased inflammatory process because an uncontrolled inflammatory reaction leads to cardiac failure. This might be a double-edged sword given that future drug therapies target the MMP system to prevent adverse remodeling. See p 2082.
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Lack of Tissue Inhibitor of Metalloproteinases 2 Leads to Exacerbated Left Ventricular Dysfunction and Adverse Extracellular Matrix Remodeling in Response to Biomechanical Stress
Tissue inhibitor of metalloproteinases 2 (TIMP2) is one of the TIMPs that is required for regulating the structural remodeling of the cardiac extracellular matrix. Tissue inhibitor of metalloproteinases 2 is the only TIMP with the unique property of activating matrix metalloproteinases 2 (MMP2) in addition to inhibiting a number of MMPs. Tissue inhibitor of metalloproteinases 2 levels are increased in the hearts of patients with aortic valvular stenosis and patients with pressure-overloaded cardiomyopathy. However, whether this rise in TIMP2 is detrimental (by activating MMP2) or beneficial (through inhibiting MMPs) to the diseased heart is not clear. Our study demonstrates that lack of TIMP2 severely compromises cardiac response to biomechanical stress through adverse structural remodeling and impaired myocyte-extracellular matrix interaction, leading to worsening of left ventricular dilation and dysfunction. On the basis of our study, the rise in TIMP2 in the hearts of patients with pressure-overloaded cardiomyopathy is a compensatory response to overcome the elevated proteolytic activities in these diseased hearts, although it may not reach a sufficiently high level to prevent the disease progression. For this reason, overexpression of TIMP2 could serve as a potential therapy in pressure-overloaded cardiomyopathy. See p 2094.
The Development of Myocardial Fibrosis in Transgenic Mice With Targeted Overexpression of Tumor Necrosis Factor Requires Mast Cell-Fibroblast Interactions
The response of the heart to injury shares many features of wound healing that are observed in the lung, kidney, and skin. For many of these tissues, including the heart, fibrosis represents a final common pathway that leads to organ dysfunction or failure. Although it is clear that progressive myocardial fibrosis is deleterious to the heart, it is not clear from the existing studies exactly how or why wound healing becomes dysregulated in the adult heart. The data from this study, which was conducted in transgenic mice, suggest that sustained inflammatory signaling leads to fibrosis indirectly through recruitment of mast cells to the myocardium, which in turn activates the resident cardiac fibroblasts to become more profibrotic. The results of this study also suggest that fibroblasts that have been exposed to sustained inflammatory signaling become more sensitive to transforming growth factor ␤ signaling. Taken together, these observations suggest that therapies designed to attenuate the effects of mast cells may be beneficial with respect to the development and progression of myocardial fibrosis in inflammatory cardiomyopathy. See p 2106.
COP9 Signalosome Regulates Autophagosome Maturation
Macroautophagy sequesters portions of the cytoplasm into doublemembrane vesicles (known as autophagosomes) for fusion with and degradation by lysosomes. Autophagy is essential to intracellular homeostasis and is involved in the pathophysiology of a variety of diseases. Targeting autophagy can potentially become a therapeutic strategy to treat heart disease; this is being intensively explored. Thus, it is critical to better understand the mechanisms that regulate autophagy, especially the selective autophagy that removes defective organelles and protein aggregates. The COP9 signalosome (CSN), a conserved protein complex consisting of 8 subunits (CSN1 through CSN8), is known to regulate the ubiquitin-proteasome system, another major intracellular proteolytic pathway. We report that mice with perinatal cardiomyocyte-restricted ablation of the Csn8 gene (CR-Csn8KO) display massive cardiomyocyte necrosis, develop dilated cardiomyopathy, and die prematurely. However, it is unknown whether CSN plays a role in autophagy. Here, we report that the fusion between autophagosomes and lysosomes is impaired in the cardiomyocytes of CR-Csn8KO mice; as a result, the removal of autophagosomes is impaired. This appears to be caused by a downregulation of Rab7, a small G protein known to be indispensable to the fusion process. Impaired autophagosome removal is likely responsible for the massive cardiomyocyte necrosis in CR-Csn8KO mice because cardiomyocytes with more severe autophagosome accumulation undergo necrosis more often in CR-Csn8KO mice and long-term lysosomal inhibition with chloroquine is sufficient to cause cardiomyocyte necrosis in mice. Therefore, we conclude that Csn8/CSN regulates both the ubiquitin-proteasome system and autophagy in the heart. See p 2117.
Intravital Microscopy on Atherosclerosis in Apolipoprotein E-Deficient Mice Establishes Microvessels as Major Entry Pathways for Leukocytes to Advanced Lesions
The invasion of leukocytes in atherosclerosis has been thought to take place mainly from the arterial lumen. However, there has been considerable speculation regarding the potential role of lesion microvessels in the recruitment of inflammatory cells to plaques. Development of a microvascular network in lesions has been associated with the transition of stable to vulnerable plaques and thus the onset of symptomatic disease. However, there has been no direct study of leukocyte recruitment from lesion microvessels, and the quantitative role of this route of entry is unclear. In this study, adventitial microvessels in advanced lesions in atherosclerotic ApoE Ϫ/Ϫ mice were studied with intravital microscopy. The data show that there is no microvascular recruitment of leukocytes during early stages of the disease in mice. Inflammatory cells are instead recruited from the arterial lumen. However, once microvascular networks develop inside lesions, venules have a capacity to recruit leukocytes that are 100-fold stronger per endothelial area than recruitment from the arterial lumen. Recruitment involves the cell adhesion molecules P-selectin, L-selectin, and P-selectin glycoprotein ligand 1. Furthermore, studies of leukocyte extravasation from lesion venules and comparison of leukocyte density in lesions with or without adventitial microvessels support that these vessels contribute to overall cell recruitment to plaques. Taken together, these data establish microvessels in atherosclerosis as important entry pathways for leukocytes to lesions. See p 2129.
